Login / Signup

Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".

Marco FalconeGiusy Tiseo
Published in: Antimicrobial agents and chemotherapy (2022)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes
  • gram negative
  • quality improvement
  • patient reported